{
    "clinical_study": {
        "@rank": "109241", 
        "arm_group": [
            {
                "arm_group_label": "Group 1 - Metformin", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Group 2 - No treatment", 
                "arm_group_type": "No Intervention"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this research is to determine the effects of Metformin, a well tolerated drug\n      widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients."
        }, 
        "brief_title": "A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women", 
        "condition": "Adenocarcinoma of the Endometrium", 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Endometrial Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological confirmed diagnosis of grade I or II adenocarcinoma of the endometrium\n\n          -  Must be obese as defined by a body mass index (BMI) greater than or equal to 30 kg/m2\n\n          -  Candidate for surgical removal of their uterus as part of their endometrial cancer\n             treatment\n\n          -  Subjects must have signed informed consent\n\n          -  Age 42 - 65 years of age\n\n          -  Electrocorticogram (ECOG) Performance status of 0 - 2\n\n          -  History of adequate renal, liver, and bone marrow function:\n\n               -  Hb: (adequate for surgical intervention, with transfusion if necessary) White\n                  Blood Cell (WBC): (normal range)\n\n               -  Platelets: (180K/cmm)\n\n               -  Liver Function Test(LFTs): Normal bilirubin (<2.0mg/dL), AST/ALT (2xULN)\n\n               -  Renal function: creatinine less than 1.4\n\n          -  Female subjects must either not be of child-bearing potential or must have a negative\n             urine pregnancy test within 7 days of randomization to Metformin. Subjects are\n             considered not of child-bearing potential if they are surgically sterile or they are\n             postmenopausal for greater than 12 months.\n\n        Exclusion Criteria:\n\n          -  Poorly differentiated cancer or any of the high-risk subtypes of endometrial cancer\n             including serous, clear cell, or carcinosarcoma\n\n          -  History of diabetes mellitus Type 1 or Type 2.\n\n          -  Receiving metformin prior to enrollment\n\n          -  Known hypersensitivity to metformin.\n\n          -  Unable to swallow and retain oral medication.\n\n          -  Pregnant or lactating.\n\n          -  Previous or concurrent malignancies, except non-melanoma skin cancers, unless\n             curatively treated and with no evidence of recurrence for > 5 years\n\n          -  If the physician feels that the candidate is not suitable for the study, he/she will\n             be excluded.\n\n          -  Currently taking biguanides, sulfonylurea drugs, thiazolidinediones, insulin, or mTOR\n             or DPP-4 inhibitors or having taken any of these medications during the 12 weeks\n             prior to study participation.\n\n          -  Currently taking any non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin and\n             unable to stop such medications due to a present medical condition.\n\n          -  Clinical symptoms of gastrointestinal obstruction or bleeding and consideration for\n             immediate surgery or immediate neoadjuvant chemoradiation.\n\n          -  History of lactic or other metabolic acidosis.\n\n          -  Uncontrolled infectious disease.\n\n          -  History of positivity for human immunodeficiency virus (HIV).\n\n          -  History of congestive heart failure requiring pharmacologic treatment.\n\n          -  History of excessive alcohol abuse, defined by a habitual intake of more than three\n             drinks daily.\n\n          -  Mal-absorption syndrome, disease affecting gastrointestinal function, or previous\n             resection of the stomach or small bowel.\n\n          -  Current use of medications for weight loss.\n\n          -  Currently taking cimetidine, thiazide diuretics or cephalexin. If a patient needs\n             some of these agents, alternative agents should be substituted."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877564", 
            "org_study_id": "138647"
        }, 
        "intervention": {
            "arm_group_label": "Group 1 - Metformin", 
            "intervention_name": "Metformin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Metformin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "June 2, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Little Rock", 
                    "country": "United States", 
                    "state": "Arkansas", 
                    "zip": "72205"
                }, 
                "name": "University of Arkansas for Medical Sciences"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "IHC-based tissue markers of proliferation:  ki67, phosphorylated histone H3, estrogen receptor (ER), progesterone receptor (PR), and telomerase (hTERT)", 
            "safety_issue": "Yes", 
            "time_frame": "1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877564"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Arkansas", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Arkansas", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}